The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology

Annals of Oncology shared a recent article by A. Alvarez Secord on X:

“New article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.”

Title: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

Authors: A. Alvarez Secord, S.N. Lewin, C.G. Murphy, S.C. Cecere, A. Barquín, F. Gálvez-Montosa, C.A. Mathews, G.E. Konecny, I. Ray-Coquard, A. Oaknin, M. J. Rubio Pérez, A. Bonaventura, E.J. Diver, S.-A. Ayuk, Y. Wang, B.R. Corr and V. Salutari

Mirvetuximab Soravtansine

More posts featuring Annals of Oncology.

Insight

A. Alvarez Secord A. Barquín Annals of Oncology B.R. Corr C.A. Mathews C.G. Murphy cancer E.J. Diver efficacy F. Gálvez-Montosa G.E. Konecny Mirvetuximab Soravtansine OncoDaily Oncology Ovarian Cancer PICCOLO Trial Platinum-Sensitive S.-A. Ayuk S.C. Cecere S.N. Lewin safety V. Salutari Y. Wang